TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8839716
Drug: Rapid Rotation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Rotation (RR) chemotherapy
Study: 1311152
Drug: Self-help dietary
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help dietary intervention for individuals responsible for meal preparation
Study: 25209738
Drug: Continuous drisapersen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous drisapersen 6 mg/kg
Study: 25209738
Drug: Intermittent drisapersen
Normalized name: drisapersen
DrugBank: Drisapersen (DB13688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent drisapersen 6 mg/kg
Study: 22732469
Drug: Cobicistat (COBI)
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cobicistat (COBI) 150 mg QD for 7 days
Study: 22732469
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 100 mg QD for 7 days
Study: 11534317
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Dalteparin) at a dose of 200 I.E./kg body weight/d
Study: 11534317
Drug: Unfragmented heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfragmented heparin
Study: 9508182
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg subcutaneously every 4 weeks; n = 69)
Study: 27546817
Drug: Indapamide SR
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide SR 1.5 mg with perindopril 2-4 mg (active treatment)
Study: 12221157
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (60 micro g)
Study: 9865236
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for the same schedule
Study: 23446658
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss (BWL) treatment
Study: 24899570
Drug: Oral preparation
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral preparation containing hyaluronic acid (Oralvisc®)
Study: 19164788
Drug: Lidocaine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1 mg/kg bolus followed by continuous infusion for 48 hours)
Study: 24105697
Drug: Placebo (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (bolus and infusion)
Study: 19164788
Drug: Lidocaine (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (lower doses)
Study: 15306109
Drug: Cialis 20
Normalized name: Cialis 20mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cialis 20 mg taken on demand
Study: 9498886
Drug: Propofol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.0 mg/kgxh
Study: 9498886
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/kgxh
Study: 9498886
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kgxh
Study: 9498886
Drug: Propofol 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.1 mg/kg bolus followed by 1.0 mg/kgxh
Study: 8192438
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of oral acyclovir daily
Study: 8192438
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of oral acyclovir daily
Study: 26823552
Drug: Ketoanalogue‐supplemented vegetarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoanalogue‐supplemented vegetarian very low‐protein diet (KD) (0.3 g/kg vegetable proteins and 1 cps/5 kg ketoanalogues per day)
Study: 26823552
Drug: Conventional low‐protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low‐protein diet (LPD) (0.6 g/kg per day)
Study: 24401580
Drug: P(cv‐a) CO2
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: P(cv‐a) CO2 guided fluid therapy (group P)
Study: 24401580
Drug: ScvO2 guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ScvO2 guided fluid therapy (group S)
Study: 26130344
Drug: TXA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA group (2 intravenous injections of 1 g TXA pre- and post-operatively)
Study: 22269195
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (mouth rinse with no antiseptic agents)
Study: 15662146
Drug: d-methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-methylphenidate hydrochloride (d-MPH) 10 mg twice-a-day
Study: 11696143
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg x kg(‐1) 0.2% ropivacaine + clonidine 2 microg x kg(‐1)
Study: 11696143
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg x kg(‐1) 0.2% ropivacaine
Study: 11074735
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (conjugated equine estrogens alone or in combination with progestins)
Study: 3932228
Drug: HB 420
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB 420 (1.75 mg)
Study: 3932228
Drug: HB 419
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB 419 (2.5 mg)
Study: 12241543
Drug: Prednisolone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (single 50 mg dose)
Study: 7587422
Drug: Inhaled salmeterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol, 50 micrograms twice a day for seven doses
Study: 2262371
Drug: Two hyperthermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two hyperthermia treatments
Study: 30756527
Drug: 120 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/d ifenprodil
Study: 30756527
Drug: 60 mg/d
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/d ifenprodil
Study: 30391912
Drug: Dexmedetomidine (Dex)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (Dex) administration
Study: 16459945
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical care plus compliance therapy (4-6 sessions, 60 minutes each)
Study: 12856387
Drug: E5564 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5564 (all doses)
Study: 10391557
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) of 25 Gy
Study: 10391557
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) of 12-20 Gy
Study: 1515884
Drug: 44 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 mg/kg of VP‐16 + 103 mg/kg CY followed by 12 Gy TBI (autologous marrow recipients)
Study: 1515884
Drug: 36 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 mg/kg of VP‐16 + 67 mg/kg CY followed by 12 Gy TBI (allogeneic marrow recipients)
Study: 1515884
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of etoposide and cyclophosphamide with TBI
Study: 1515884
Drug: Dose limiting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose limiting toxicities
Study: 24766166
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages
Study: 25187903
Drug: Endosseous implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endosseous implants with straight emergence profile, ZirTi surface, 3.3 to 5 mm diameter, and 8.5 to 13 mm length
Study: 21812893
Drug: Rosiglitazone/Metformin (Rosi/Met,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone/Metformin (Rosi/Met, 4/1000 mg)
Study: 17998769
Drug: Cilnidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (10 mg)
Study: 29311072
Drug: Cefiderocol 100
Normalized name: cefiderocol 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefiderocol 100 mg
Study: 29311072
Drug: Cefiderocol 250
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 250 mg
Study: 29311072
Drug: Cefiderocol 2000
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 2000 mg
Study: 29311072
Drug: Cefiderocol 1000
Normalized name: cefiderocol 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefiderocol 1000 mg q8h
Study: 29311072
Drug: Cefiderocol 2000
Normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cefiderocol 2000 mg q8h
Study: 12488964
Drug: Structured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured group treatment and teaching programmes for Type I diabetes
Study: 12488964
Drug: Structured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured group treatment and teaching programmes for non-insulin dependent Type II diabetes
Study: 12488964
Drug: Structured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured group treatment and teaching programmes for hypertension
Study: 12488964
Drug: Phased approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phased approach defining sequential stages of a continuum of increasing evidence
Study: 10512131
Drug: IL-2 alone
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 alone at 6 x 10(6) Cetus units/m2 3 days weekly
Study: 2022713
Drug: Daily metGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily metGH
Study: 7075659
Drug: Indalpine (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indalpine (a selective 5‐HT uptake inhibitor) administered for 3 days
Study: 15456080
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day)
Study: 15456080
Drug: Peginterferon alpha-2b
Normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day) plus amantadine (200 mg per day)
Study: 5067672
Drug: Inert capsule
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert capsule (control)
Study: 25226826
Drug: Echium oil
Normalized name: Echium plantagineum seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echium oil (10 g daily providing 1.2 g of SDA)
Study: 21646672
Drug: Hospital-specific factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-specific factors affecting blood pressure treatment
Study: 9523054
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium infusion
Study: 19199498
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium infusion
Study: 19199498
Drug: High-dose magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose magnesium infusion
Study: 15544588
Drug: Loratadine 5
Normalized name: loratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 5 mg/day (2.5 mg/day for children ≤24 months of age)
Study: 3365283
Drug: Indalpine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indalpine (50 mg/d and 150 mg/d)
Study: 31189238
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment combined with TCM syndrome differentiation
Study: 18289334
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg thrice weekly (on Monday, Wednesday, and Saturday) for the first month, 250 mg thrice weekly for the second month, and 250 mg twice weekly for the third month.
Study: 18289334
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg/day for three months.
Study: 8179541
Drug: Terbutaline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.25 mg subcutaneously)
Study: 30668243
Drug: CRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP plus 8.5% doxycycline hyclate gel
Study: 30668243
Drug: CRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP plus 2% clindamycin hydrochloride gel
Study: 29776987
Drug: 150-μg subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-μg subcutaneous glucagon (MDG)
Study: 29776987
Drug: 50% basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% basal insulin reduction
Study: 29776987
Drug: 40-g oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-g oral glucose tablets
Study: 26610183
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy (rESWT) with nightly splinting
Study: 19195847
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics (AP)
Study: 11152919
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate in one tablet daily (n = 768)
Study: 18219129
Drug: IVIg treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg treatment guided by RT‐PCR
Study: 523424
Drug: Cholintheophyllinate (Euspirax)
Normalized name: chlortheophylline
DrugBank: 8-chlorotheophylline (DB14132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholintheophyllinate (Euspirax) 400 mg
Study: 523424
Drug: Theophyllin‐Aethylendiamine (Euphyllin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophyllin‐Aethylendiamine (Euphyllin retard) 350 mg
Study: 26975890
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (up to 15 L/min to maintain SpO2 of 94% or higher) (n=145)
Study: 23964144
Drug: 45 mL
Normalized name: ethanol 0.645 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mL of NaP + 20 mg of bisacodyl (prep 2)
Study: 23964144
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of PEG (prep 3)
Study: 23964144
Drug: NaP preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaP preparations (comparing all NaP preparations to PEG preparations)
Study: 20466530
Drug: AZD4818 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4818 300 mug twice daily
Study: 16489477
Drug: Continuous passive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous passive motion for 1 hour, twice a day, following total knee replacement surgery.
Study: 8494127
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg, twice daily
Study: 8494127
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg, twice daily
Study: 30431725
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) switched off
Study: 30431725
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) switched on
Study: 26931110
Drug: Patient-controlled oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled oral analgesia
Study: 26931110
Drug: Parenteral analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral analgesia
Study: 17222352
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (control group)
Study: 9678143
Drug: Prostaglandin gel
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin gel with hygroscopic cervical dilators
Study: 8008103
Drug: Patient point-of-view
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient point-of-view (PPOV1) delivery of regularly ordered medication by a pharmacy technician to the nurse server once a day
Study: 8008103
Drug: Patient point-of-view
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient point-of-view (PPOV2) delivery of all medications (including stats and i.v.s) to the nurse server hourly between 0700 and 2300 hours
Study: 8008103
Drug: Traditional medication
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medication cart
Study: 31763300
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin (0.4 mg/ml) applied for 5 min
Study: 17724829
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with prostamol Uno and tamsulosin
Study: 17724829
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with prostamol Uno
Study: 11391683
Drug: Bowman-Birk inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowman-Birk inhibitor concentrate (BBIC)
Study: 9521027
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy and treatment with HSE
Study: 1092765
Drug: Purified type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified type 1 M protein vaccine
Study: 24127444
Drug: Intravenous arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous arsenic trioxide (ATO) 0.16 mg/kg
Study: 24127444
Drug: Oral tetra-arsenic
Normalized name: Tetra-arsenic tetra-sulfide
DrugBank: Tetraarsenic tetrasulfide (DB19141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tetra-arsenic tetra-sulfide (RIF) plus ATRA
Study: 26403986
Drug: Intravenous arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous arsenic trioxide (ATO) plus ATRA
Study: 12201825
Drug: Physiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological dose (0.0017 mg/kg/day)
Study: 12201825
Drug: Physiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological dose (0.0033 mg/kg/day)
Study: 12201825
Drug: Supraphysiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological dose (0.010 mg/kg/day)
Study: 12201825
Drug: Supraphysiological dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological dose (0.025 mg/kg/day)
Study: 12201825
Drug: Overall increase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall increase in GH dose
Study: 7863248
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nizatidine nocte (n = 86)
Study: 7863248
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 150 mg/d nizatidine (n = 93)
Study: 7863248
Drug: nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 150 mg nocte (116 patients)
Study: 7863248
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 150 mg nizatidine daily (121 patients)
Study: 782497
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of beclomethasone dipropionate
Study: 21334655
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg alone
Study: 25465944
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg with Tamsulosin 0.2 mg
Study: 19060462
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream plus colchicine tablets (1-2 g/day)
Study: 19060462
Drug: Colchicine tablets
Normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine tablets (1-2 g/day)
Study: 14679365
Drug: Red Grape
Normalized name: CVS Children's Cold & Cough Elixir (Red Grape)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Grape Juice (RGJ) 500 ml/day
Study: 11179106
Drug: NO2 (10-μg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO2 (10-μg/m3 increment)
Study: 11179106
Drug: TSP (10-μg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSP (10-μg/m3 increment)
Study: 11179106
Drug: O3 (10-μg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: O3 (10-μg/m3 increment)
Study: 9215818
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 100 mg/m2 orally on days 1 to 14, methotrexate 40 mg/m2 intravenously on days 1 and 8, fluorouracil 600 mg/m2 intravenously on days 1 and 8)
Study: 9215818
Drug: LMF (chlorambucil
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMF (chlorambucil 5 mg/m2 orally on days 1 to 14 with some I.V. cytostatic drugs)
Study: 26826622
Drug: Sirolimus eluting
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus eluting stents (SES) in insulin-treated patients
Study: 26826622
Drug: Paclitaxel eluting
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel eluting stents (PES) in insulin-treated patients
Study: 23451852
Drug: Pimecrolimus 1%
Normalized name: PIMECROLIMUS 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimecrolimus 1% cream applied twice daily for 2 months
Study: 17944760
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy intervention (n = 34)
Study: 19032300
Drug: Ephedrine 10
Normalized name: pseudoephedrine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 10 mg